Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma
Article Abstract:
Oral montelukast and inhaled beclomethasone both effectively reduce the symptoms of chronic asthma. Researchers treated 895 patients with either montelukast, beclomethasone, or a placebo for four months. Montelukast therapy was associated with a 13% improvement in forced expiratory volume (FEV1), a measure of lung volume and function, while beclomethasone improved FEV1 7%. Both drugs reduced asthma symptoms, reduced asthma-associated sleep disturbances, and reduced the number of asthma attacks.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
How do corticosteroids work in asthma?
Article Abstract:
The physiology of asthma and how corticosteroid drugs suppress airway inflammation in asthmatic patients are reviewed. Topics include the molecular basis of inflammation in asthma, chromatin remodeling, cellular effects of corticosteroids, glucocorticoid receptors, corticosteroid-induce gene transcription, switching off inflammatory genes, corticosteroid interactions with other drugs, corticosteroid resistance, and therapeutic implications.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Long-term methotrexate treatment in corticosteroid-dependent asthma. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
- Abstracts: Cheiroarthropathy and long term diabetic complications in Nigerians. part 2 Limited joint mobility in children and adolescents with insulin dependent diabetes mellitus
- Abstracts: Surgical treatment of brain metastases in malignant melanoma. Cardiac metastases
- Abstracts: Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer. part 2 Symptoms and rehabilitation needs of patients with early stage breast cancer during primary therapy
- Abstracts: Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma: a National Biotherapy Study Group trial